{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:07:04Z","timestamp":1790842024644,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T00:00:00Z","timestamp":1303862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Extensive drug resistance of <jats:italic>Acinetobacter baumannii<\/jats:italic> is a serious problem in the clinical setting. It is therefore important to find active antibiotic combinations that could be effective in the treatment of infections caused by this problematic 'superbug'. In this study, we analyzed the <jats:italic>in vitro<\/jats:italic> activities of three colistin-based combinations and a minocycline-based combination against clinically isolated extensive drug resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> (XDR-AB) strains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fourteen XDR-AB clinical isolates were collected. The clonotypes were determined by polymerase chain reaction-based fingerprinting. Susceptibility testing was carried out according to the standards of the Clinical and Laboratory Standards Institute. Activities of drug combinations were investigated against four selected strains and analyzed by mean survival time over 12 hours (MST<jats:sub>12 h<\/jats:sub>) in a time-kill study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The time-kill studies indicated that the minimum inhibitory concentration (MIC) of colistin (0.5 or 0.25 \u03bcg\/mL) completely killed all strains at 2 to 4 hours, but 0.5\u00d7MIC colistin showed no bactericidal activity. Meropenem (8 \u03bcg\/mL), minocycline (1 \u03bcg\/mL) or rifampicin (0.06 \u03bcg\/mL) did not show bactericidal activity. However, combinations of colistin at 0.5\u00d7MIC (0.25 or 0.125 \u03bcg\/mL) with each of the above were synergistic and shown bactericidal activities against all test isolates. A combination of meropenem (16 \u03bcg\/mL) with minocycline (0.5\u00d7MIC, 4 or 2 \u03bcg\/mL) was synergitic to all test isolates, but neither showed bactericidal activity alone. The MST<jats:sub>12 h<\/jats:sub> values of drug combinations (either colistin- or minocycline-based combinations) were significantly shorter than those of the single drugs (<jats:italic>p<\/jats:italic> &lt; 0.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study indicates that combinations of colistin\/meropenem, colistin\/rifampicin, colistin\/minocycline and minocycline\/meropenem are synergistic in vitro against XDR-AB strains.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-11-109","type":"journal-article","created":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T18:24:10Z","timestamp":1303928650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients"],"prefix":"10.1186","volume":"11","author":[{"given":"Wang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,27]]},"reference":[{"key":"1441_CR1","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1128\/AAC.01464-06","volume":"51","author":"F Perez","year":"2007","unstructured":"Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA: Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007, 51: 3471-3484. 10.1128\/AAC.01464-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR2","first-page":"325","volume":"10","author":"F Wang","year":"2010","unstructured":"Wang F, Zhu DM, Hu FP, Ruan FY, Ni YX, Song JY: CHINET 2009 surveillance of bacterial resistance in China. Chin J Infect Chemother. 2010, 10: 325-334.","journal-title":"Chin J Infect Chemother"},{"key":"1441_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007, 6: 29-40. 10.1038\/nrd2201.","journal-title":"Nat Rev Drug Discov"},{"key":"1441_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR: Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006, 6: 589-601. 10.1016\/S1473-3099(06)70580-1.","journal-title":"Lancet Infect Dis"},{"key":"1441_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijantimicag.2009.06.021","volume":"34","author":"E Bishburg","year":"2009","unstructured":"Bishburg E, Bishburg K: Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009, 34: 395-401. 10.1016\/j.ijantimicag.2009.06.021.","journal-title":"Int J Antimicrob Agents"},{"key":"1441_CR6","first-page":"103","volume":"23","author":"FJ Candel","year":"2010","unstructured":"Candel FJ, Calvo N, Head J, S\u00e1nchez A, Matesanz M, Culebras E: A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Rev Esp Quimioter. 2010, 23: 103-108.","journal-title":"Rev Esp Quimioter"},{"key":"1441_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00431-009-1137-3","volume":"169","author":"E Iosifidis","year":"2010","unstructured":"Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V: Colistin administration to pediatric and neonatal patients. Eur J Pediatr. 2010, 169: 867-874. 10.1007\/s00431-009-1137-3.","journal-title":"Eur J Pediatr"},{"key":"1441_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/00365540903147001","volume":"41","author":"C Santamar\u00eda","year":"2009","unstructured":"Santamar\u00eda C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P: Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis. 2009, 41: 767-769. 10.1080\/00365540903147001.","journal-title":"Scand J Infect Dis"},{"key":"1441_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/mdr.2008.0840","volume":"14","author":"CH Lee","year":"2008","unstructured":"Lee CH, Tang YF, Su LH, Chien CC, Liu JW: Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. Microb Drug Resist. 2008, 14: 233-237. 10.1089\/mdr.2008.0840.","journal-title":"Microb Drug Resist"},{"key":"1441_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijantimicag.2005.10.012","volume":"27","author":"F Timurkaynak","year":"2006","unstructured":"Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO: vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and A.baumannii isolated from intensive care units. Int J Antimicrob Agents. 2006, 27: 224-228. 10.1016\/j.ijantimicag.2005.10.012.","journal-title":"Int J Antimicrob Agents"},{"key":"1441_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1128\/AAC.00689-07","volume":"52","author":"GA Pankuch","year":"2008","unstructured":"Pankuch GA, Lin G, Seifert H, Appelbaum PC: Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother. 2008, 52: 333-336. 10.1128\/AAC.00689-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3855\/jidc.604","volume":"4","author":"CH Rodriguez","year":"2010","unstructured":"Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, Radice M, Gutkind G, Vay C, Famiglietti A: vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries. 2010, 4: 164-167.","journal-title":"J Infect Dev Ctries"},{"key":"1441_CR13","first-page":"161","volume":"93","author":"P Pongpech","year":"2010","unstructured":"Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A: Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai. 2010, 93: 161-171.","journal-title":"J Med Assoc Thai"},{"key":"1441_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1128\/AAC.00858-06","volume":"51","author":"JS Hawley","year":"2007","unstructured":"Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR: Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother. 2007, 51: 376-378. 10.1128\/AAC.00858-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jac\/dkm178","volume":"60","author":"TY Tan","year":"2007","unstructured":"Tan TY, Ng LS, Tan E, Huang G: vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007, 60: 421-423. 10.1093\/jac\/dkm178.","journal-title":"J Antimicrob Chemother"},{"key":"1441_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1086\/528867","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Karageorgopoulos DE: Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008, 46: 1121-1122. 10.1086\/528867.","journal-title":"Clin Infect Dis"},{"key":"1441_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1086\/502307","volume":"25","author":"S Silbert","year":"2004","unstructured":"Silbert S, Pfaller MA, Hollis RJ, Barth AL, Sader HS: Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol. 2004, 25: 847-851. 10.1086\/502307.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1441_CR18","unstructured":"Clinical and Laboratory Standard Institute: Performance standards for antimicrobial susceptibility testing, Nineteenth informational supplement. CLSI document M100 S19. 2009, Wayne PA. USA"},{"key":"1441_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3855\/jidc.604","volume":"4","author":"CH Rodriguez","year":"2010","unstructured":"Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K: vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries. 2010, 4: 164-167.","journal-title":"J Infect Dev Ctries"},{"key":"1441_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","volume":"45","author":"J Li","year":"2001","unstructured":"Li J, Turnidge J, Milne R, Nation RL, Coulthard K: vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001, 45: 781-785. 10.1128\/AAC.45.3.781-785.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jinf.2008.11.002","volume":"58","author":"W Yau","year":"2009","unstructured":"Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH: Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect. 2009, 58: 138-144. 10.1016\/j.jinf.2008.11.002.","journal-title":"J Infect"},{"key":"1441_CR22","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1021\/jp100458x","volume":"114","author":"SJ Wallace","year":"2010","unstructured":"Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ: Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B. 2010, 114: 4836-4840. 10.1021\/jp100458x.","journal-title":"J Phys Chem B"},{"key":"1441_CR23","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.01361-08","volume":"53","author":"D Plachouras","year":"2009","unstructured":"Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I: Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009, 53: 3430-3436. 10.1128\/AAC.01361-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1128\/AAC.01114-09","volume":"54","author":"RV Dudhani","year":"2010","unstructured":"Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J: Elucidation of the pharmacokinetic\/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother. 2010, 54: 1117-1124. 10.1128\/AAC.01114-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ: Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005, 27: 1329-1342. 10.1016\/j.clinthera.2005.09.005.","journal-title":"Clin Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-11-109\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:38:05Z","timestamp":1630503485000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-11-109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-11-109","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,27]]},"assertion":[{"value":"13 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"109"}}